Methods and compositions using immunomodulatory compounds in combination therapy

A technology of immune regulation and composition, which can be applied in the direction of drug combination, anhydride/acid/halide active ingredients, pharmaceutical formulations, etc., can solve problems such as increasing the activity of hematopoietic stem cell proliferation and self-renewal
CN101495111AInactive Publication Date: 2009-07-29CELGENE CORP
37 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
CELGENE CORP
Publication Date
2009-07-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Provided herein are compositions comprising one or more immunomodulatory compounds and valproic acid, hydroxyurea or trichostatin A, methods for their use in CD34+ hematopoietic stem cell expansion in vitro and in vivo for bone marrow reconstitution and bone marrow transplantation, increasing fetal hemoglobin expression, and methods for treating, preventing and / or managing cancer, tumors and hematological diseases and disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to US Provisional Application No. 60 / 808,602, filed May 26, 2006, the entire contents of which are incorporated herein by reference. 1. Technical field

[0002] The present invention provides compositions comprising one or more immunomodulatory compounds and valproic acid, hydroxyurea, or trichostatin A for the in vitro and in vivo expansion of CD34+ hematopoietic stem cells for bone marrow reconstitution and bone marrow transplantation. Methods of increasing fetal hemoglobin expression, and methods of treating, preventing and / or managing cancer, tumors and hematological diseases and disorders. 2. Background technology

[0003] 2.1 IMiDs TM

[0004] Numerous studies have been conducted with the aim of providing compounds that are safe and effective in the treatment of diseases associated with abnormal TNF-α production, see, eg, Marriott, J.B., et al. Expert Opin. Biol. Ther. 1(4): 1-8 (2001); G.W. Muller, et al. Journal of Medicinal ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More